Crescent Biopharma Unveils Preclinical Data for CR-001 PD-1 x VEGF Bispecific Antibody Ahead of Phase 1 Trial

Reuters11-04

Crescent Biopharma Unveils Preclinical Data for CR-001 PD-1 x VEGF Bispecific Antibody Ahead of Phase 1 Trial

Crescent Biopharma Inc. announced that preclinical data for its investigational drug candidate CR-001, a tetravalent bispecific antibody targeting PD-1 and VEGF for the treatment of solid tumors, will be presented at the Society for Immunotherapy of Cancer's $(SITC)$ 40th Annual Meeting, scheduled for November 7-9, 2025. According to the company, CR-001 demonstrated cooperative pharmacology and robust anti-tumor activity in preclinical models, with increased T-cell activation and tumor growth reduction. An Investigational New Drug (IND) submission is planned for the fourth quarter of 2025 to support the initiation of a global Phase 1 clinical trial in patients with solid tumors in the first quarter of 2026. The abstract is available on SITC's website, and the poster presentation will be accessible on Crescent's website on the day of the presentation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568215-en) on November 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580730358?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580730358","market":"nz","top_or_hot":-1,"title":"Crescent Biopharma Unveils Preclinical Data for CR-001 PD-1 x VEGF Bispecific Antibody Ahead of Phase 1 Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Crescent Biopharma Unveils Preclinical Data for CR-001 PD-1 x VEGF Bispecific Antibody Ahead of Phase 1 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CBIO\">Crescent Biopharma Inc</a>. announced that preclinical data for its investigational drug candidate CR-001, a tetravalent bispecific antibody targeting PD-1 and VEGF for the treatment of solid tumors, will be presented at the Society for Immunotherapy of Cancer's <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 40th Annual Meeting, scheduled for November 7-9, 2025. According to the company, CR-001 demonstrated cooperative pharmacology and robust anti-tumor activity in preclinical models, with increased T-cell activation and tumor growth reduction. An Investigational New Drug (IND) submission is planned for the fourth quarter of 2025 to support the initiation of a global Phase 1 clinical trial in patients with solid tumors in the first quarter of 2026. The abstract is available on SITC's website, and the poster presentation will be accessible on Crescent's website on the day of the presentation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568215-en) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crescent Biopharma Unveils Preclinical Data for CR-001 PD-1 x VEGF Bispecific Antibody Ahead of Phase 1 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrescent Biopharma Unveils Preclinical Data for CR-001 PD-1 x VEGF Bispecific Antibody Ahead of Phase 1 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Crescent Biopharma Unveils Preclinical Data for CR-001 PD-1 x VEGF Bispecific Antibody Ahead of Phase 1 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CBIO\">Crescent Biopharma Inc</a>. announced that preclinical data for its investigational drug candidate CR-001, a tetravalent bispecific antibody targeting PD-1 and VEGF for the treatment of solid tumors, will be presented at the Society for Immunotherapy of Cancer's <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 40th Annual Meeting, scheduled for November 7-9, 2025. According to the company, CR-001 demonstrated cooperative pharmacology and robust anti-tumor activity in preclinical models, with increased T-cell activation and tumor growth reduction. An Investigational New Drug (IND) submission is planned for the fourth quarter of 2025 to support the initiation of a global Phase 1 clinical trial in patients with solid tumors in the first quarter of 2026. The abstract is available on SITC's website, and the poster presentation will be accessible on Crescent's website on the day of the presentation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568215-en) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL6dGjKr:1","article_id":"2580730358","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580730358","pubTimestamp":1762265119,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Crescent Biopharma Inc. announced that preclinical data for its investigational drug candidate CR-001, a tetravalent bispecific antibody targeting PD-1 and VEGF for the treatment of solid tumors, will be presented at the Society for Immunotherapy of Cancer's  40th Annual Meeting, scheduled for November 7-9, 2025. According to the company, CR-001 demonstrated cooperative pharmacology and robust anti-tumor activity in preclinical models, with increased T-cell activation and tumor growth reduction. An Investigational New Drug  submission is planned for the fourth quarter of 2025 to support the initiation of a global Phase 1 clinical trial in patients with solid tumors in the first quarter of 2026. The abstract is available on SITC's website, and the poster presentation will be accessible on Crescent's website on the day of the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ti","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","CBIO":"Crescent Biopharma Inc","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Crescent Biopharma在1期试验前公布CR-001 PD-1 x VEGF双特异性抗体的临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CBIO":0.9,"NDAQ":0.9},"content_text":"Crescent Biopharma Unveils Preclinical Data for CR-001 PD-1 x VEGF Bispecific Antibody Ahead of Phase 1 Trial\n    \n\nCrescent Biopharma Inc. announced that preclinical data for its investigational drug candidate CR-001, a tetravalent bispecific antibody targeting PD-1 and VEGF for the treatment of solid tumors, will be presented at the Society for Immunotherapy of Cancer's $(SITC)$ 40th Annual Meeting, scheduled for November 7-9, 2025. According to the company, CR-001 demonstrated cooperative pharmacology and robust anti-tumor activity in preclinical models, with increased T-cell activation and tumor growth reduction. An Investigational New Drug (IND) submission is planned for the fourth quarter of 2025 to support the initiation of a global Phase 1 clinical trial in patients with solid tumors in the first quarter of 2026. The abstract is available on SITC's website, and the poster presentation will be accessible on Crescent's website on the day of the presentation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568215-en) on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580730358","isCrawlerRequest":true}